The effects of industry sponsorship on comparator selection in trial registrations for neuropsychiatric conditions in children

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Dunn, Adam G ^a   Mand, Kenneth D ^b,c   Coiera, Enrico ^a   Bourgeois, Florence T ^b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHILD; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; DRUG THERAPY; HUMANS; NEUROPSYCHIATRY; RESEARCH DESIGN;

EID: 84893261668     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084951     Document Type: Article

References (47)

1. Bourgeois FT, Murthy S, Pinto C, Olson KL, Ioannidis JP et al. (2012) Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics 130: 285-292. doi:10.1542/peds.2012-0139. PubMed: 22826574.
2. Cohen E, Goldman RD, Ragone A, Uleryk E, Atenafu EG et al. (2010) Child vs adult randomized controlled trials in specialist journals: a citation analysis of trends, 1985-2005. Arch Pediatr Adolesc Med 164: 283-288. doi:10.1001/archpediatrics.2009.291. PubMed: 20194264.
3. Sammons HM, Choonara I (2005) Clinical trials of medication in children, 1996-2002. Eur J Clin Pharmacol 61: 165-167. doi:10.1007/s00228-005-0894-9. PubMed: 15761753.
4. Watts G (2007) WHO launches campaign to make drugs safer for children. BMJ 335: 1227. doi:10.1136/bmj.39423.581042.DB. PubMed: 18079526.
5. Cox ER, Halloran DR, Homan SM, Welliver S, Mager DE (2008) Trends in the Prevalence of Chronic Medication Use in Children: 2002-2005. Pediatrics 122: e1053-e1061. doi:10.1542/peds.2008-0214. PubMed: 18977954.
6. Olfson M, Marcus SC, Weissman MM, Jensen PS (2002) National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 41: 514-521. doi:10.1097/00004583-200205000-00008. PubMed: 12014783. (Pubitemid 38338129)
7. Rani F, Murray ML, Byrne PJ, Wong IC (2008) Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121: 1002-1009. doi:10.1542/peds.2007-2008. PubMed: 18450906.
8. Zito JM, Safer DJ, DosReis S, Gardner JF, Magder L et al. (2003) Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 157: 17-25. doi:10.1001/archpedi.157.1.17. PubMed: 12517190. (Pubitemid 36343413)
9. Cooper WO, Arbogast PG, Ding H, Hickson GB, Fuchs DC et al. (2006) Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr 6: 79-83. doi:10.1016/j.ambp.2005.11.002. PubMed: 16530143. (Pubitemid 43960577)
10. Hunkeler EM, Fireman B, Lee J, Diamond R, Hamilton J et al. (2005) Trends in use of antidepressants, lithium, and anticonvulsants in Kaiser Permanente-insured youths, 1994-2003. J Child Adolesc Psychopharmacol 15: 26-37. doi:10.1089/cap.2005.15.26. PubMed: 15741783. (Pubitemid 40365911)
11. Czaja AS, Valuck R (2012) Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence. Pharmacoepidemiol Drug Saf 21: 997-1004. doi:10.1002/pds.3312. PubMed: 22760843.
12. Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS et al. (2012) Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics 129: e771-e784. doi:10.1542/peds.2011-2158. PubMed: 22351885.
13. Malozowski S (2008) Comparative efficacy: what we know, what we need to know, and how we can get there. Ann Intern Med 148: 702-703. doi:10.7326/0003-4819-148-9-200805060-00010. PubMed: 18458283.
14. Sorenson C, Naci H, Cylus J, Mossialos E (2011) Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ 343: d4849. doi:10.1136/bmj.d4849. PubMed: 21896610.
15. Stafford RS, Wagner TH, Lavori PW (2009) New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N Engl J Med 361: 1230-1233. doi:10.1056/NEJMp0906490. PubMed: 19675326.
16. Salanti G, Kavvoura FK, Ioannidis JP (2008) Exploring the geometry of treatment networks. Ann Intern Med 148: 544-553. doi: 10.7326/0003-4819-148-7- 200804010-00011. PubMed: 18378949. (Pubitemid 351665420)
17. Arruda MA (2013) NO evidence of efficacy or evidence of no efficacy. JAMA Pediatr 167: 300-302. doi:10.1001/jamapediatrics.2013.1105. PubMed: 23358915.
18. Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P (2008) Greater Response to Placebo in Children Than in Adults: A Systematic Review and Meta-Analysis in Drug-Resistant Partial Epilepsy. PLoS Med 5: e166. doi:10.1371/journal.pmed. 0050166. PubMed: 18700812.
19. Bourgeois FT, Murthy S, Mandl KD (2012) Comparative effectiveness research: an empirical study of trials registered in ClinicalTrials.gov. PLOS ONE 7: e28820. doi:10.1371/journal.pone.0028820. PubMed: 22253698.
20. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL et al. (2000) The uncertainty principle and industry-sponsored research. Lancet 356: 635-638. doi:10.1016/S0140-6736(00)02605-2. PubMed: 10968436. (Pubitemid 30627590)
21. Hochman M, McCormick D (2010) Characteristics of published comparative effectiveness studies of medications. JAMA 303: 951-958. doi:10.1001/jama.2010. 240. PubMed: 20215609.
22. Estellat C, Ravaud P (2012) Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch Intern Med 172: 237-244. doi:10.1001/archinternmed.2011.1209. PubMed: 22332155.
23. Vitiello B, Heiligenstein JH, Riddle MA, Greenhill LL, Fegert JM (2004) The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration. Biol Psychiatry 56: 3-9. doi:10.1016/j.biopsych.2004.03.011. PubMed: 15219466. (Pubitemid 38813399)
24. Clinicaltrials.gov. Available: http://clinicaltrials.gov. Accessed 2012 May 2
25. WHO Collaborating Centre for Drug Statistics Methodology International language for drug utilization research: Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD).
26. Dunn AG, Bourgeois FT, Murthy S, Mandl KD, Day RO et al. (2012) The role and impact of research agendas on the comparative-effectiveness research among antihyperlipidemics. Clin Pharmacol Ther 91: 685-691. doi:10.1038/clpt.2011.279. PubMed: 22378152.
27. Kappagoda S, Ioannidis JPA (2012) Neglected tropical diseases: survey and geometry of randomised evidence. BMJ 345: e6512. PubMed: 23089149.
28. Dunn AG, Westbrook JI (2011) Interpreting social network metrics in healthcare organisations: A review and guide to validating small networks. Soc Sci Med 72: 1064-1068. PubMed: 21371798.
29. Freeman LC (1978) Centrality in social networks conceptual clarification. Social Networks 1: 215-239. doi:10.1016/0378-8733(78)90021-7.
30. Anderson BS, Butts C, Carley K (1999) The interaction of size and density with graph-level indices. Social Networks 21: 239-267. doi:10.1016/S0378- 8733(99)00011-8.
31. Salanti G, Higgins JP, Ades AE, Ioannidis JP (2008) Evaluation of networks of randomized trials. Stat Methods Med Res 17: 279-301. PubMed: 17925316.
32. Hurlbert SH (1971) The Nonconcept of Species Diversity: A Critique and Alternative Parameters. Ecology 52: 577-586. doi:10.2307/1934145.
33. Cohen E, Goldman RD, Ragone A, Uleryk E, Atenafu EG et al. (2010) Child vs adult randomized controlled trials in specialist journals: A citation analysis of trends, 1985-2005. Arch Pediatr Adolesc Med 164: 283-288. doi:10.1001/archpediatrics.2009.291. PubMed: 20194264.
34. Cohen E, Uleryk E, Jasuja M, Parkin PC (2007) An absence of pediatric randomized controlled trials in general medical journals, 1985-2004. J Clin Epidemiol 60: 118-123. doi:10.1016/j.jclinepi.2006.03.015. PubMed: 17208117. (Pubitemid 46039874)
35. Pasquali SK, Lam WK, Chiswell K, Kemper AR, Li JS (2012) Status of the Pediatric Clinical Trials Enterprise: An Analysis of the US Available online at: ClinicalTrials.gov Registry. Pediatrics
36. Caldwell PH, Murphy SB, Butow PN, Craig JC (2004) Clinical trials in children. Lancet 364: 803-811. doi:10.1016/S0140-6736(04)16942-0. PubMed: 15337409. (Pubitemid 39165102)
37. Smyth RL, Weindling AM (1999) Research in children: ethical and scientific aspects. Lancet 354 Suppl 2: SII21-24
38. Steinbrook R (2002) Testing medications in children. N Engl J Med 347: 1462-1470. doi:10.1056/NEJMhpr021646. PubMed: 12409558.
39. DeMauro SB, Giaccone A, Kirpalani H, Schmidt B (2011) Quality of reporting of neonatal and infant trials in high-impact journals. Pediatrics 128: e639-e644. PubMed: 21859916.
40. Thomson D, Hartling L, Cohen E, Vandermeer B, Tjosvold L et al. (2010) Controlled trials in children: quantity, methodological quality and descriptive characteristics of pediatric controlled trials published 1948-2006. PLOS ONE 5: ([MedlinePgn:]) PubMed: 20927344.
41. Stang A, Hense H-W, Jöckel K-H, Turner EH, Tramèr MR (2005) Is It Always Unethical to Use a Placebo in a Clinical Trial? PLoS Med 2: e72. doi:10.1371/journal.pmed.0020072. PubMed: 15783259.
42. Roberts LW, Lauriello J, Geppert C, Keith SJ (2001) Placebos and paradoxes in psychiatric research: an ethics perspective. Biol Psychiatry 49: 887-893. doi:10.1016/S0006-3223(01)01111-8. PubMed: 11377406. (Pubitemid 32493810)
43. Temple R, Ellenberg SS (2000) Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues. Ann Intern Med 133: 455-463. doi:10.7326/0003-4819-133-6- 200009190-00014. PubMed: 10975964.
44. Lathyris DN, Patsopoulos NA, Salanti G, Ioannidis JP (2010) Industry sponsorship and selection of comparators in randomized clinical trials. Eur J Clin Invest 40: 172-182. doi:10.1111/j.1365-2362.2009.02240.x. PubMed: 20050879.
45. Leucht S, Corves C, Arbter D, Engel RR, Li C et al. (2009) Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31-41. doi:10.1016/S0140-6736(08)61764-X. PubMed: 19058842.
46. Rizos EC, Salanti G, Kontoyiannis DP, Ioannidis JP (2011) Homophily and co-occurrence patterns shape randomized trials agendas: illustration in antifungal agents. J Clin Epidemiol 64: 830-842. doi:10.1016/j.jclinepi.2010.11. 017. PubMed: 21411286.
47. Stafford RS, Wagner TH, Lavori PW (2009) New, but Not Improved? Incorporating Comparative-Effectiveness Information into FDA Labeling. N Engl J Med 361: 1230-1233. doi:10.1056/NEJMp0906490. PubMed: 19675326. Development